Novo Nordisk licenses Hengrui obesity pill

Unbranded obesity drug pills on lab bench illustrating global oral obesity licensing deal

Key Points

01Novo Nordisk secures global rights to HRS-1596 outside Greater China
02Deal for oral GLP-1/GIP drug candidate valued up to $2.6 billion
03Hengrui receives $300 million upfront plus milestones and royalties
04HRS-1596 is phase 1-ready, with China cleared to start trials

Novo Nordisk and Hengrui sign major HRS-1596 deal

Novo Nordisk has entered an exclusive license agreement with Hengrui Pharma for HRS-1596, an experimental glucagon-like peptide-1 receptor and gastric inhibitory polypeptide receptor dual agonist. The arrangement gives Novo Nordisk the exclusive right to develop, manufacture and commercialise the candidate globally, excluding mainland China, Hong Kong, Macao and Taiwan.

The potential total value of the deal is up to $2.6 billion. This includes an upfront payment of $300 million to Hengrui Pharma, with the balance tied to development, regulatory and commercial milestones, as well as royalties based on net sales in Novo Nordisk’s licensed territories.

Profile of HRS-1596 and therapeutic focus

HRS-1596 is described as phase 1-ready and is intended for once-weekly oral dosing. As a dual GLP-1 and GIP receptor agonist, it is designed to address obesity, type 2 diabetes and other metabolic diseases.

The candidate aims to reduce body weight and improve glycaemic control through several mechanisms. These include appetite suppression, stimulation of insulin secretion and improved insulin sensitivity, supporting its potential use across multiple metabolic indications.

Development status and regional responsibilities

Within China, Hengrui Pharma has received approval to initiate phase 1 clinical trials of HRS-1596 for weight management and type 2 diabetes. This positions HRS-1596 to enter human testing in that market while Novo Nordisk prepares development plans for other regions.

Under the licensing structure, Hengrui retains rights in mainland China, Hong Kong, Macao and Taiwan, while Novo Nordisk holds exclusive rights in the rest of the world. Hengrui will also be eligible for royalties on net sales generated in Novo Nordisk’s territories if the drug reaches the market.

Regulatory conditions and expected closing timeline

Completion of the license agreement is subject to clearance under the U.S. Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. These requirements must be satisfied before the transaction can take full effect.

Both companies expect the transaction to close in the fourth quarter of 2026, subject to the necessary approvals. Until closing, HRS-1596 remains at the phase 1-ready stage, with early clinical work beginning under Hengrui’s approval in China.

Key Takeaways

01The HRS-1596 agreement significantly expands Novo Nordisk’s access to an oral GLP-1/GIP candidate while leaving Hengrui with rights in Greater China.
02The structure of upfront, milestone and royalty payments aligns incentives around successful global development and commercialisation of HRS-1596.
03Regulatory clearance and early clinical progress will be key milestones as the once-weekly oral candidate advances in obesity and type 2 diabetes programs.

References